Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Alport Syndrome | Case report

Tale of two nephropathies; co-occurring Alport syndrome and IgA nephropathy, a case report

Authors: Aniruddha Bhattacharyya, Yuting Huang, Sarah Hussain Khan, Cinthia Beskow Drachenberg, Laura C. Malone

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Alport Syndrome and IgA Nephropathy (IgAN) are both disorders that can cause hematuria. Alport syndrome is most commonly an X-linked disease, caused by COL4A5 mutation. Mutations of COL4A3 and COL4A4 on chromosome two are also common causes of Alport syndrome. IgAN is the most common glomerulonephritis worldwide. Though IgAN is usually sporadic, an estimated 15% of cases have an inheritable component. These cases of Familal IgA Nephropathy (FIgAN) can have mutations on genes which are known to cause Alport Syndrome.

Case presentation

We report a case of a 27-year-old man with strong family history of renal disease, who presented with hematuria and new non-nephrotic range proteinuria. Physical exam showed no abnormalities. His creatinine remained persistently elevated, and renal ultrasound exhibited bilaterally increased echogenicity consistent with Chronic Kidney Disease. Twenty-four-hour urinary collection revealed non-nephrotic range proteinuria of 1.4 g, with otherwise negative workup. On biopsy, he had IgA positive immunofluorescent staining as well as moderate interstitial fibrosis and tubular atrophy. Electron microscopy showed a basket-weave pattern of thickening and splitting of the lamina densa-consistent with Alport Syndrome, as well as mesangial expansion with electron-dense deposits -consistent with IgAN.

Conclusions

Mutations of COL4A5 on the X chromosome, as well as mutations of COL4A3 and COL4A4 on chromosome 2, can cause both Alport Syndrome and FIgAN. Genome wide association studies identified certain Angiotensin Converting Enzyme gene polymorphisms as independent risk factors for progression of IgAN. Our Presentation with this co-occurring pathology suggests a new paradigm where Alport Syndrome and FIgAN may represent manifestations of a single disease spectrum rather than two disparate pathologies. Appreciating hematuria through this framework has implications for treatments and genetic counseling. Further genome wide association studies will likely increase our understanding of Alport Syndrome, FIgAN, and other causes of hematuria.
Literature
1.
go back to reference Yeo SC, Barratt J. Immunoglobulin a nephropathy and related disorders. In Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Tonelli M. National Kidney Foundation’s primer on kidney diseases. 7th ed. Philadelphia: Elsevier; 2018. Yeo SC, Barratt J. Immunoglobulin a nephropathy and related disorders. In Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Tonelli M. National Kidney Foundation’s primer on kidney diseases. 7th ed. Philadelphia: Elsevier; 2018.
2.
go back to reference Feehally J, Floege J. Immunoglobulin a nephropathy and IgA Vasculitis (Henoch-Schonlein Purpura). In Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018. Feehally J, Floege J. Immunoglobulin a nephropathy and IgA Vasculitis (Henoch-Schonlein Purpura). In Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018.
3.
go back to reference Gregory MC. Alport syndrome and related disorders. In: Feehally J, Floege J, Tonelli M, Johnson RJ, editors. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018. Gregory MC. Alport syndrome and related disorders. In: Feehally J, Floege J, Tonelli M, Johnson RJ, editors. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018.
4.
go back to reference Rheault MN, Kashtan CE. Alport syndrome and other familial glomerular syndromes. In: Feehally J, Floege J, Tonelli M, Johnson RJ, editors. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018. Rheault MN, Kashtan CE. Alport syndrome and other familial glomerular syndromes. In: Feehally J, Floege J, Tonelli M, Johnson RJ, editors. Comprehensive clinical nephrology. 6th ed. New York: Elsevier; 2018.
5.
go back to reference Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18(8):2408–15.CrossRef Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18(8):2408–15.CrossRef
6.
go back to reference Gale DP. How benign is hematuria? Using genetics to predict prognosis. Pediatr Nephrol. 2013;28(8):1183–93.CrossRef Gale DP. How benign is hematuria? Using genetics to predict prognosis. Pediatr Nephrol. 2013;28(8):1183–93.CrossRef
7.
go back to reference Stapleton CP, Kennedy C, Fennelly NK, Murray SL, Connaughton DM, Dorman AM, et al. An exome sequencing study of 10 families with IgA nephropathy. Nephron. 2020;144(2):72–83.CrossRef Stapleton CP, Kennedy C, Fennelly NK, Murray SL, Connaughton DM, Dorman AM, et al. An exome sequencing study of 10 families with IgA nephropathy. Nephron. 2020;144(2):72–83.CrossRef
8.
go back to reference Murray SL, Fennelly NK, Doyle B, Lynch SA, Conlon PJ. Integration of genetic and histopathology data in interpretation of kidney disease. Nephrol Dial Transplant. 2020;35(7):1113–32.CrossRef Murray SL, Fennelly NK, Doyle B, Lynch SA, Conlon PJ. Integration of genetic and histopathology data in interpretation of kidney disease. Nephrol Dial Transplant. 2020;35(7):1113–32.CrossRef
9.
go back to reference Neugut YD, Kiryluk K. Genetic determinants of IgA nephropathy: Western perspective. Semin Nephrol. 2018;38(5):443–54 WB Saunders.CrossRef Neugut YD, Kiryluk K. Genetic determinants of IgA nephropathy: Western perspective. Semin Nephrol. 2018;38(5):443–54 WB Saunders.CrossRef
10.
go back to reference Stephen I, Hsu H, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000;57(5):1818–35.CrossRef Stephen I, Hsu H, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000;57(5):1818–35.CrossRef
Metadata
Title
Tale of two nephropathies; co-occurring Alport syndrome and IgA nephropathy, a case report
Authors
Aniruddha Bhattacharyya
Yuting Huang
Sarah Hussain Khan
Cinthia Beskow Drachenberg
Laura C. Malone
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02567-9

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.